Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Eribulin Mesylate Use as Third-Line Therapy in Patients With Metastatic Breast Cancer (VESPRY): A Prospective, Multicentre, Observational StudyTher Adv Med Oncol 2018 Dec 19;[EPub Ahead of Print], V Adamo, GRR Ricciardi, D Giuffrida, G Scandurra, A Russo, L Blasi, P Spadaro, C Iacono, HJ Soto Parra, A Savarino, F Ferraú, F Zerilli, F Verderame, A Butera, C Santangelo, V Franchina, M Caruso
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.